Total: $152.15M (Year total: $152.15M)

AIT Therapeutics Inc., of Garden City, N.Y.

Circassia Pharmaceuticals Inc., of Oxford, U.K.

$3.15

For the successful completion of a pre-submission meeting with the FDA for AIT's cylinder-free nitric oxide generator and phasic-flow delivery system, Airnovent, for use in the hospital setting

2/5/19

Evotec AG (Hamburg, Germany)

Celgene Corp. (Summit, N.J.)

$14.00

For the advancement of a program into the lead optimization stage developed from Evotec's compound library using its induced pluripotent stem cell-based screening platform

1/9/19

Evotec AG (Hamburg, Germany)

Second Genome Inc. (South San Francisco)

$2.00

For the start of a phase II study with SGM-1019, described as an oral therapeutic for the treatment of nonalcoholic steatohepatitis

1/25/19

Genmab A/S (Copenhagen)

Johnson & Johnson (New Brunswick, N.J.)

$75.00

Sales volume milestone in its Darzalex (daratumumab) collaboration with Janssen Biotech Inc., a unit of New Brunswick, N.J.-based Johnson & Johnson, triggered by confirmation from Janssen that sales of the multiple myeloma drug reached $2B in the 2018 calendar year

1/9/19

Hookipa Pharma Inc. (New York)

Gilead Sciences Inc. (Foster City, Calif.)

N/A

For designing and delivering 14 research-grade vectors to Gilead, along with the characterization of those vectors and delivery of a data package for the HIV program

1/3/19

Oramed Pharmaceuticals Inc. (Jerusalem)

Hefei Tianhui Incubator of Technologies Co. Ltd. (Hefei, China)

$3.00

In association with the licensing deal for Oramed's orally ingestible insulin capsule (ORMD-0801) in greater China

1/9/19

Seres Therapeutics Inc. (Cambridge, Mass.)

Nestle Health Science

$40.00

For the start of the pivotal phase IIb ECO-RESET study testing microbiome candidate SER-287

1/4/19

Sosei Group Corp. (Tokyo)

Astrazeneca plc (Cambridge, U.K.)

$15.00

For reaching a clinical milestone with next-generation immuno-oncology candidate AZD-4635, an adenosine 2A receptor antagonist

1/8/19

Notes

Currency conversions are based on exchange rates at the time of the deal.

This chart includes only biotech companies that develop therapeutics.